Journal of the Korean Applied Science and Technology (한국응용과학기술학회지)

The Korean Society of Applied Science and Technology (한국응용과학기술학회)
권호 표지
DOI QR코드

DOI QR Code

Synthesis and EGFR Inhibitory Activity of 6-Guanidinoquinazoline Derivatives

6-구아니디노퀴나졸린 유도체의 합성 및 EGFR 저해 활성

  • Yoo, Kyung-Ho (Biomaterials Research Center, Korea Institute of Science and Technology) ;
  • Lee, Yeo-Ran (Biomaterials Research Center, Korea Institute of Science and Technology)
  • 유경호 (한국과학기술연구원 바이오소재연구센터) ;
  • 이여란 (한국과학기술연구원 바이오소재연구센터)
  • Published : 2008.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The central role of tyrosine phosphorylation in cell proliferative signaling mechanisms provides another target for chemotherapy. The aim of this research is to develop new quinazoline derivatives that possess the inhibitory activity for depidermal growth factor receptor (EGFR) tyrosine kinase (TK) as protein kinase inhibitors. In this work, a series of new 4-anilino-6-guanidino-7-methoxyquinazoline derivatives (12a-l) were synthesized by the introduction of guanidine moiety at C-6 of quinazoline nucleus and evaluated for their EGFR TK inhibitory activities.

Keywords

References

  1. A. C. Porter and R. R. Vaillancourt, Tyrosine Kinase Receptor-activated Signal Transduction Pathways Which Lead to Oncogenesis, Oncogene, 17, 1343 (1998) https://doi.org/10.1038/sj.onc.1202171
  2. P. Blume-Jensen and Tony Hunter, Oncogenic Kinase Signalling, Nature, 411, 355 (2001) https://doi.org/10.1038/35077225
  3. A. Levitzki, Protein Tyrosine Kinase Inhibitors as Therapeutic Agents, Pharmacol. Ther., 82, 231 (1999) https://doi.org/10.1016/S0163-7258(98)00066-7
  4. R. Tibes, J. Trent, and R. Kurzrock, Tyrosine Kinase Inhibitors and the Dawn of Molecular Cancer Therapeutics, Ann. Rev. Pharmacol. Toxicol., January 6, 2005
  5. P. Traxler and P. Furet, Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors, Pharmacol. Ther., 82, 195 (1999) https://doi.org/10.1016/S0163-7258(98)00044-8
  6. D. W. Fry, A. J. Kraker, A. McMichael, L. A. Ambroso, J. M. Nelson, W. R. Leopold, R. W. Connors, and A. J. Bridges, A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, Science, 265, 1093 (1994) https://doi.org/10.1126/science.8066447
  7. J. Vesel, L. Havlicek, M. Strnad, J. J. Blow, A. Donella-Deana, L. Pinna, D. S. Letham, J.-y. Kato, L. Detkvaud, S. Leclerc, and L. Meijere, Inhibition of Cyclin-dependent Kinases by Purine Analogues, Eur. J. Biochem., 224, 771 (1994) https://doi.org/10.1111/j.1432-1033.1994.00771.x
  8. E. Weisberg, P. Manley, J. Mestan, S. Cowan-Jacon, A. Ray, and D. Griffin, AMN107 (nilotinib): A Novel and Selective Inhibitor of BCR-ABL. Brit. J. Canver, 94, 1765 (2006) https://doi.org/10.1038/sj.bjc.6603170
  9. D. Raben, B. A. Helfrich, D. Chan, G. Johnson, and P. A. Bunn, Jr., ZD1839, A Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Alone and in Combination with Radiation and Chemotherapy as a New Therapeutic Strategy in Non-small Cell Lung Cancer, Semin. Oncol., 29 (Supplement 4), 37 (2002) https://doi.org/10.1053/sonc.2002.31521
  10. R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. M. Clark, P. Santabarbara, and P. Bonomi, Determinants of Tumor Response and Survival with Erlotinib in Patients with Non-Small-Cell Lung Cancer, J. Clin. Oncol., 22, 3238 (2004) https://doi.org/10.1200/JCO.2004.11.057
  11. Burris H. A. 3rd, Hurwitz H. I., Dees E. C., Dowlati A., Blackwell K. L., O'Neil B., Marcom P. K., Ellis M. J., Overmoyer B., Jones S. F., Harris J. L., Smith D. A., Koch K. M., Stead A., Mangum S., and Spector N. L., Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), A Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients with Metastatic Carcinomas, J Clin. Oncol., 23, 5305 (2005) https://doi.org/10.1200/JCO.2005.16.584
  12. B. Moy, P. Kirkpatrick, S. Kar, and P. Goss, Lapatinib, Nature Rev. Drug Discov. 6, 431 (2007) https://doi.org/10.1038/nrd2332
  13. C. C. Price, N. J. Leonard, and D. Y. Curtin, 4-(4'-Diethylamino-1'- methylbutylamino)-7-chloroquinazoline, J. Amer. Chem. Soc. 68, 1305 (1946) https://doi.org/10.1021/ja01211a058
  14. J. Parrick and R. Ragunathan, Studies of Phthalazine-5,8-quinone, A Ring Contraction, and Some Novel and Potentially Useful Fluorescent Phthalimides, J. Chem. Soc., Perkin Trans. 1, 211 (1993)
  15. A. J. Bridges, H. Zhou, D. R. Cody, G. W. Rewcastle, A. McMichael, H. D. H. Showalter, D. W. Fry, A. J. Kraker, and W. A. Denny, Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4- (3-Bromoanilino)-6,7-dimethoxyquinazoline (PD153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor, J. Med. Chem., 39, 267 (1996) https://doi.org/10.1021/jm9503613
  16. O. Tabarrini, V. Cecchetti, A. Fravolini, G. Nocentini, A. Barzi, S. Sabatini, H. Miao, and C. Sissi, Design and Synthesis of Modified Quinolones as Antitumoral Acridones, J. Med. Chem., 42, 2136 (1999) https://doi.org/10.1021/jm980324m